Carbetocin

Long-acting oxytocin analogEmerging

Carbetocin is a long-acting oxytocin analog. Carbetocin is a deaminated, carba-substituted oxytocin analog whose modifications resist enzymatic degradation and extend its half-life well beyond that of oxytocin, allowing a single injection where oxytocin needs an infusion. It binds uterine oxytocin receptors to trigger rhythmic myometrial contraction and sustained uterine tone.

Calculate Dose

For research use only.

Key Facts

CAS: 37025-55-1
Molecular Weight (MW): 988.2 g/mol
Half-life: —
FDA status: Not Approved
Evidence level: Clinical Trial Evidence
Human dose established: Yes
Administration Route: Intramuscular · Intravenous · Intranasal
Frequency: Single dose after delivery (postpartum hemorrhage trials); three times daily (Prader-Willi nasal trials)
Last updated: Nov 7, 2026
Reviewed: Nov 7, 2026

Research summary

Long-acting synthetic oxytocin analog used in many countries to prevent uterine atony and postpartum haemorrhage after caesarean delivery. It is not approved by the FDA in the United States.

Research evidence

Regulatory review (FDA label)None in reviewed sources
Controlled human trials4 reviewed sources
Early or uncontrolled human studiesNone in reviewed sources
Lab & animal studiesNone in reviewed sources

How it works

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

Peptide Library's Carbetocin profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.

Carbetocin dosage evidence

Carbetocin has no FDA-approved dosage; there is no carbetocin label on DailyMed. Human dosing comes from trials: a single 100 mcg injection right after birth, intramuscular after vaginal birth in the WHO CHAMPION trial and intravenous at planned caesarean delivery, and a separate nasal-spray programme in Prader-Willi syndrome that tested 3.2 mg and 9.6 mg three times daily and did not meet its primary endpoints.

Clinical Trial Evidence

Dosage evidence summary for Carbetocin
Human dosing established	Yes
Route	Intramuscular · Intravenous · Intranasal
Frequency	Single dose after delivery (postpartum hemorrhage trials); three times daily (Prader-Willi nasal trials)
Duration studied	One dose after birth; 8–12 weeks in the Prader-Willi trials
Evidence level	Clinical Trial Evidence
Last reviewed	2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Carbetocin, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
WHO CHAMPION trial — heat-stable carbetocin after vaginal birth, NEJM 2018Clinical trial · Randomised, double-blind noninferiority trial	Women giving birth vaginally at 23 sites in 10 countries (29,645 randomised)	Heat-stable carbetocin 100 mcg, or oxytocin 10 IU	Intramuscular	Once, immediately after birth	Single dose	Blood loss of at least 500 mL or extra uterotonics: 14.5% with carbetocin versus 14.4% with oxytocin (noninferior); noninferiority was not shown for blood loss of at least 1,000 mL (1.51% versus 1.45%)	Heat-Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth. N Engl J Med. 2018.
Planned caesarean delivery — Oslo trial, BJOG 2025 (NCT03899961)Clinical trial · Double-blind randomised controlled trial	Women aged 18–50 with a singleton pregnancy having a planned caesarean delivery (240 randomised, 215 treated)	Carbetocin 100 mcg, or oxytocin 2.5 IU	Intravenous	Once, immediately after delivery	Single dose	No difference in troponin change (primary endpoint) or estimated blood loss; rescue treatment was needed less often with carbetocin (27.2% versus 46.4%)	Effects of Prophylactic Oxytocin or Carbetocin on Troponin Release and Postpartum Haemorrhage at Planned Caesarean Delivery: A Double-Blind Randomised Controlled Trial. BJOG. 2025.
CARE-PWS — phase 3, intranasal carbetocin in Prader-Willi syndrome (NCT03649477)Clinical trial · Randomised, double-blind, placebo-controlled phase 3 trial	Children and adolescents aged 7–18 with Prader-Willi syndrome (n=130; enrolment stopped early because of COVID-19)	9.6 mg or 3.2 mg per dose, or placebo	Intranasal	Three times daily	8-week placebo-controlled period, then 56 weeks of follow-up	Primary endpoints (hyperphagia and obsessive-compulsive scores, 9.6 mg versus placebo) improved numerically but not significantly; the 3.2 mg arm showed nominally significant improvements; flushing was the most common adverse event	Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial. J Clin Endocrinol Metab. 2023.
COMPASS PWS — phase 3 confirmatory trial, nasal spray (NCT06173531)Clinical trial · Randomised, placebo-controlled phase 3 trial	People with Prader-Willi syndrome (n=175)	3.2 mg, or placebo	Intranasal	Three times daily	12 weeks	Primary endpoint not met: hyperphagia score changed by -4.8 with carbetocin and -5.1 with placebo (P = 0.79), with no separation on any secondary endpoint	Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 COMPASS PWS Study. Clin Ther. 2026.

Where sources disagree

Carbetocin is a long-acting oxytocin analog. The postpartum doses are a single 100 mcg injection right after birth; the Prader-Willi doses were milligram amounts by nasal spray. The two are not interchangeable.
The FDA has not approved carbetocin for any use. The confirmatory COMPASS PWS trial found no benefit over placebo for hyperphagia in Prader-Willi syndrome.

Carbetocin dosage in published studies and labels →

Sequence & molecular data

Sequence and molecular data for Carbetocin
Molecular formula	C45H69N11O12S
Molecular weight	988.2 g/mol
CAS number	37025-55-1
PubChem CID	16681432
FDA UNII	88TWF8015Y
ChEMBL	CHEMBL3301668
DrugBank	DB01282

Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.

Science

Mechanism of Action

Carbetocin is a deaminated, carba-substituted oxytocin analog whose modifications resist enzymatic degradation and extend its half-life well beyond that of oxytocin, allowing a single injection where oxytocin needs an infusion. It binds uterine oxytocin receptors to trigger rhythmic myometrial contraction and sustained uterine tone.

Studies

Research statistics

388 PubMed publications · 44.2% human clinical research · 96 registered trials

Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted

Regulatory & research status

Carbetocin is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

Regulatory and research status for Carbetocin
FDA status	Not Approved
Research status	Research-only compound; no approval pathway listed
Availability	Prescription-Only
WADA (sport)	Unknown / Not Listed
Library classification	Clinical Trial

How FDA approval, compounding and research-only status differ

Benefits

—

Carbetocin side effects

No side effects listed yet for this entry.

Storage & stability

This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.

Carbetocin: frequently asked questions

What is Carbetocin?

Long-acting synthetic oxytocin analog used in many countries to prevent uterine atony and postpartum haemorrhage after caesarean delivery. It is not approved by the FDA in the United States.

How does Carbetocin work?

Is Carbetocin FDA approved?

No. Carbetocin is not approved by the FDA for any indication and is categorised as prescription-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

What peptides are similar to Carbetocin?

Compounds most often compared with Carbetocin include Oxytocin, Atosiban, ARA 290 (Cibinetide) and Serelaxin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

References

Related research, comparisons & guides

Related peptides

Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2

This Carbetocin profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error

Track Carbetocin research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →